表紙
市場調査レポート

エピジェネティクス:新しい標的、利用可能な技術、専門家へのインタビューおよびエピジェネティックコミュニティの展望

Epigenetics: Emerging Targets, Available Technologies, Expert Interviews, and an Epigenetic Community Perspective

発行 Insight Pharma Reports 商品コード 62858
出版日 ページ情報 英文 83 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
エピジェネティクス:新しい標的、利用可能な技術、専門家へのインタビューおよびエピジェネティックコミュニティの展望 Epigenetics: Emerging Targets, Available Technologies, Expert Interviews, and an Epigenetic Community Perspective
出版日: 2013年11月01日 ページ情報: 英文 83 Pages
概要

当レポートでは、エピジェネティクスの技術、エピジェネティック標的および市場展望を提供しており、エピジェネティック標的に関する背景情報と調査される理由、および主要企業のプロファイルを提供しており、概略下記の構成でお届けいたします。

パートI:エピジェネティクスの背景・標的情報

第1章

  • エピジェネティクスとは?
  • ヒストン修飾
    • ヒストンメチルトランスフェラーゼ
    • アルギニンメチルトランスフェラーゼ(RMT)
    • ヒストンデメチラーゼ
    • エピジェネティックリーダー

パートII:産業における標的

第2章

  • Constellation Pharmaceuticals
  • 企業背景
  • 研究領域
    • SWI/SNF
    • EZH2
    • DOT1L
    • BETブロモドメイン
  • 直面する試練
  • 競合上の優位性
  • 提携
  • 将来の試み
  • Robert Sims氏へのインタビュー

第3章

  • EpiTherapeutics
  • 企業背景
  • 研究領域
    • PLU1
    • FBXL10
    • GASC1
  • 直面する試練
  • 競合上の優位性
  • 提携
  • 将来の試み
  • Martin Bonde氏へのインタビュー

第4章

  • Epizyme Inc.
  • 企業背景
  • 研究領域
    • DOT1L
    • EZH2
  • 直面する試練
  • 競合上の優位性
  • 提携
  • 将来の試み
  • Jesse Smith氏へのインタビュー

パートIII:前途有望な技術・企業戦略

第5章

  • Active Motif
  • 企業背景
  • クロマチン免疫沈降(ChIP)技術
  • 競合上の優位性
  • 直面する試練
  • ChIP、ChIP-chip および ChIP-Seqを用いた抗体の認証
  • 提携・戦略
  • 将来の試み
  • Kyle Hondorp氏へのインタビュー

第6章

  • Cayman Chemical
  • 企業背景
  • アプリケーション
    • 時間分解蛍光共鳴エネルギー転移(TR-FRET)アッセイ
    • S-アデノシル-L-メチオニン(SAM)-スクリーナーアッセイ
  • 直面する試練
  • 提携
  • 将来の展望
  • Dr. Levi Blazerへのインタビュー

第7章

  • Reaction Biology Corporation
  • 企業背景
  • エピジェネティクスにおけるReaction Biology Corporationの役割
  • 競合戦略
  • 提携
  • 将来の展望
  • Haiching Ma氏へのインタビュー

パートIV:コミュニティにおけるエピジェネティクス

第8章

  • 調査結果
  • 調査範囲
  • 市場展望
  • 提携

参考資料

Cambridge Healthtech Instituteについて

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

This report covers several technologies, epigenetic targets, and market outlook. The first part of this report covers necessary background information, mostly pertaining to epigenetic targets, and the reasons they are being investigated. Several companies have kindly disclosed several strategies, methods, and techniques that they use for either target identification or technology development.

Report Features Include:

  • Survey data results
  • Company background information
  • Interviews with CEOs, CSOs, and Expert Scientists
  • Specific pharmaceutical/biopharmaceutical companies and their strategies

In Part I of the report, several targets and their properties are discussed including histone methyltransferases, histone demethylases, and bromodomains. A list of known histone modifications is also present. This includes companies (if applicable), targets being studied, diseases they are associated with, and their clinical developmental status. Part II details specific pharmaceutical/biopharmaceutical companies and their strategies behind their target identifications and validation. These companies include Constellation Pharmaceuticals, Epizyme Inc., and EpiTherapeutics. Part III of the report covers technologies and assays available from the following biotechnology companies: Active Motif (including ChIP technology and a current list of validated antibodies), Cayman Chemical, and Reaction Biology.

Areas covered for Parts I and II include:

  • Company backgrounds
  • Areas of interest
  • Challenges encountered
  • Competitive advantages
  • Partnerships

Additionally, these sections also include interviews with CEOs, CSOs, and expert scientists of the participating companies.

The last section of the report, Part IV, gives insight into the epigenetics community. Insight Pharma Reports polled a survey which had more than 150 responses. Specific areas highlighted are targets under investigation, market outlook, and how partnerships with external organizations have advanced the industry.

Table of Contents

Executive Summary

Part I: Epigenetic Background and Target Information

Chapter 1

  • What is epigenetics?
  • Histone modifications
    • Histone methyltransferases
    • Arginine methyltransferases (RMT)
    • Histone demethylases
    • Epigenetic readers

Part II: Targets in the Industry

Chapter 2

  • Constellation Pharmaceuticals
  • Company background
  • Areas of research
    • SWI/SNF
    • EZH2
    • DOT1L
    • BET bromodomains
  • Challenges encountered
  • Competitive advantage
  • Partnerships
  • Future endeavors
  • Interview with Robert Sims
    • Company background
    • Research objectives
    • Benefits and challenges
    • Future endeavors

Chapter 3

  • EpiTherapeutics
  • Company background
  • Areas of research
    • PLU1
    • FBXL10
    • GASC1
  • Chemistry platform
  • Challenges encountered
  • Competitive advantage
  • Partnerships and future endeavors
  • Interview with Martin Bonde
    • Company background
    • Areas of research
    • Chemistry platform
    • Challenges encountered
    • Competitive advantage
    • Partnerships
    • Future endeavors

Chapter 4

  • Epizyme Inc.
  • Company background
  • Areas of research
    • DOT1L
    • EZH2
  • Challenges encountered
  • Competitive advantage
  • Partnerships
  • Future endeavors
  • Interview with Jesse Smith
    • Background
    • Areas of research
    • Target validation
    • Use of biomarkers
    • Challenges encountered
    • Partnerships
    • Future endeavors

Part III: Rising Technologies and Company Strategies

Chapter 5

  • Active Motif
  • Company background
  • Chromatin Immunoprecipitation (ChIP) technology
  • Competitive advantage
  • Challenges encountered
  • Validating antibodies using ChIP, ChIP-chip, and ChIP-Seq
  • Partnerships and strategies
  • Future endeavors
  • Interview with Kyle Hondorp
    • Company background
    • Immunoprecipitation technology
    • Challenges encountered
    • Future endeavors
    • Partnerships and growth

Chapter 6

  • Cayman Chemical
  • Company background
  • Applications
    • Time-resolved fluorescence resonance energy transfer (TR-FRET) assays
    • S-adenosyl-L-methionine (SAM)-screener assays
  • Challenges encountered
  • Partnerships
  • Future outlook
  • Interview with Dr. Levi Blazer
    • Company background
    • Partnerships
    • Areas of research
    • Assays
    • Challenges encountered
    • Future endeavors

Chapter 7

  • Reaction Biology Corporation
  • Company background
  • Reaction Biology Corporation's role in epigenetics
  • Competitive strategies
  • Partnerships
  • Future outlook
  • Interview with Haiching Ma
    • Company background
    • Areas of research
    • Partnerships
    • Future expectations

Part IV: Epigenetics in the Community

Chapter 8

  • Survey results
  • Areas of study
  • Market outlook
  • Partnerships

References

About Cambridge Healthtech Institute

Tables

  • Table 1.1 List of known histone modifications in vertebrates
  • Table 1.2: Targets and their developmental status
  • Table 5.1: Validated antibodies using ChIP, ChIP-chip, and ChIP-Seq assays

Figures

  • Figure 1.1: Interest in epigenetic targets over time
  • Figure 5.1: ChIP-chip validation steps
  • Figure 5.2: ChIP antibody validation steps
  • Figure 8.1: Survey participants
  • Figure 8.2: Popular areas of study
  • Figure 8.3: Technology of choice
  • Figure 8.4: Targets of interest
  • Figure 8.5: Expected diseases to benefit from therapeutic applications
  • Figure 8.6: Classes expected to receive FDA approval
  • Figure 8.7: Participants in partnerships
  • Figure 8.8: Impact of partnerships on research
Back to Top